Fibroblast growth factor receptors as treatment targets in clinical oncology
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fibroblast growth factor receptors as treatment targets in clinical oncology
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 16, Issue 2, Pages 105-122
Publisher
Springer Nature
Online
2018-10-26
DOI
10.1038/s41571-018-0115-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
- (2018) S T Kim et al. ANNALS OF ONCOLOGY
- Frequent Coamplification of Receptor Tyrosine Kinase and Downstream Signaling Genes in Japanese Primary Gastric Cancer and Conversion in Matched Lymph Node Metastasis
- (2018) Arnaldo N. S. Silva et al. ANNALS OF SURGERY
- The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer
- (2018) Tingting Lu et al. CANCER LETTERS
- Abstract PD4-07: Genenomic landscape of breast cancers with FGFR1 amplification and FGFR1/CCND1 co-amplification revealed by targeted capture next generation sequencing
- (2018) PI Gonzalez-Ericsson et al. CANCER RESEARCH
- Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor
- (2018) Marie-Pierre Collin et al. ChemMedChem
- Molecular Markers Increase Precision of the European Association of Urology Non–Muscle-Invasive Bladder Cancer Progression Risk Groups
- (2018) Kim E.M. van Kessel et al. CLINICAL CANCER RESEARCH
- Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors
- (2018) Manman Wei et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1
- (2018) Binyan Lin et al. GENE
- Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression
- (2018) Qianjin Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure
- (2018) Alexandra M. Haugh et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Kinase-targeted cancer therapies: progress, challenges and future directions
- (2018) Khushwant S. Bhullar et al. Molecular Cancer
- Generation of high-affinity, internalizing anti-FGFR2 single-chain variable antibody fragment fused with Fc for targeting gastrointestinal cancers
- (2018) Aleksandra Borek et al. PLoS One
- Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling
- (2018) Vincent Plagnol et al. PLoS One
- 2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4
- (2018) Thomas Knoepfel et al. ACS Medicinal Chemistry Letters
- Signature program: a platform of basket trials
- (2018) Eric D. Slosberg et al. Oncotarget
- Driver Fusions and Their Implications in the Development and Treatment of Human Cancers
- (2018) Qingsong Gao et al. Cell Reports
- Construction of a human monoclonal antibody against bFGF for suppression of NSCLC
- (2018) Sheng Wang et al. Journal of Cancer
- Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine
- (2018) Masaru Katoh Journal of Thoracic Disease
- Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in Prostate Tumor Progression
- (2018) Qianjin Li et al. NEOPLASIA
- Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.
- (2018) Vicky Makker et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results.
- (2018) Chung-Han Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- A metabolic function of FGFR3-TACC3 gene fusions in cancer
- (2018) Véronique Frattini et al. NATURE
- 2-Oxo-3, 4-dihydropyrimido[4, 5- d ]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors
- (2017) Xueqiang Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors
- (2017) Weiyan Cheng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
- (2017) Eugene J. Pietzak et al. EUROPEAN UROLOGY
- A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma
- (2017) Liqin Wang et al. EUROPEAN UROLOGY
- The integration of genomics testing and functional proteomics in the era of personalized medicine
- (2017) Masaru Katoh Expert Review of Proteomics
- Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents
- (2017) Qiang Gao et al. GASTROENTEROLOGY
- Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
- (2017) Yvette W. Jeske et al. GYNECOLOGIC ONCOLOGY
- Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas
- (2017) John K. Cowell et al. INTERNATIONAL JOURNAL OF CANCER
- Anti-FGFR1 aptamer-tagged superparamagnetic conjugates for anticancer hyperthermia therapy
- (2017) Przemysław M Jurek et al. International Journal of Nanomedicine
- Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
- (2017) Tomohiro Nishina et al. INVESTIGATIONAL NEW DRUGS
- Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck
- (2017) Till Sebastian Clauditz et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer
- (2017) Wei Zhu et al. JOURNAL OF MEDICINAL CHEMISTRY
- An mRNA Gene Expression–Based Signature to Identify FGFR1-Amplified Estrogen Receptor–Positive Breast Tumors
- (2017) Jingqin Luo et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases
- (2017) Frank Hilberg et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Breast cancer
- (2017) Nadia Harbeck et al. LANCET
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets
- (2017) Ellen Heitzer et al. MODERN PATHOLOGY
- Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications
- (2017) Lorena Lazo de la Vega et al. MOLECULAR CANCER RESEARCH
- High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer
- (2017) Aleksandra Sokolowska-Wedzina et al. MOLECULAR CANCER RESEARCH
- The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance
- (2017) Eleni Venetsanakos et al. MOLECULAR CANCER THERAPEUTICS
- Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β
- (2017) Wen Min Lau et al. MOLECULAR CANCER THERAPEUTICS
- Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
- (2017) Timothy P.S. Perera et al. MOLECULAR CANCER THERAPEUTICS
- PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2 mutant Endometrial Cancers
- (2017) Leisl M. Packer et al. MOLECULAR CANCER THERAPEUTICS
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
- (2017) Alison M. Schram et al. Nature Reviews Clinical Oncology
- Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
- (2017) Alexander Drilon et al. Nature Reviews Clinical Oncology
- Cholangiocarcinoma — evolving concepts and therapeutic strategies
- (2017) Sumera Rizvi et al. Nature Reviews Clinical Oncology
- The evolving genomic landscape of urothelial carcinoma
- (2017) Alexander P. Glaser et al. Nature Reviews Urology
- Comprehensive Genomic Profiling of 282 Pediatric Low‐ and High‐Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures
- (2017) Adrienne Johnson et al. ONCOLOGIST
- Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach
- (2017) Marco Presta et al. PHARMACOLOGY & THERAPEUTICS
- Genomic profiling of ER + breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
- (2017) Jennifer M. Giltnane et al. Science Translational Medicine
- A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
- (2017) Michael Michael et al. Targeted Oncology
- Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2–Amplified Gastric Cancer Patient–Derived Cell Model
- (2017) Jiryeon Jang et al. Translational Oncology
- 2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors
- (2017) Cheng Mo et al. ACS Medicinal Chemistry Letters
- New Horizons for Precision Medicine in Biliary Tract Cancers
- (2017) Juan W. Valle et al. Cancer Discovery
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
- (2017) Christophe Massard et al. Cancer Discovery
- Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer
- (2017) Hui Liu et al. Cancer Discovery
- High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors
- (2017) Céline Chauvin et al. Cell Reports
- Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases
- (2017) Stephanie U. Greer et al. Genome Medicine
- FGFR3–TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle
- (2017) Sourav Sarkar et al. Open Biology
- Abstract B27: Improved survival with erdafitinib (JNJ-42756493) and PD-1 blockade mediated by enhancement of anti-tumor immunity in an FGFR2-driven genetically engineered mouse model of lung cancer
- (2017) Sangeetha Palakurthi et al. Cancer Immunology Research
- FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells
- (2017) Lukasz Turczyk et al. NEOPLASIA
- A Versatile Tumor Gene Deletion System Reveals a Crucial Role for FGFR1 in Breast Cancer Metastasis
- (2017) Wei Wang et al. NEOPLASIA
- Bladder cancer
- (2017) Oner Sanli et al. Nature Reviews Disease Primers
- Gastric adenocarcinoma
- (2017) Jaffer A. Ajani et al. Nature Reviews Disease Primers
- Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway
- (2016) Jason T. Huse et al. ACTA NEUROPATHOLOGICA
- Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology
- (2016) Ibrahim Qaddoumi et al. ACTA NEUROPATHOLOGICA
- Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer withFGFR1amplification: A single-arm, phase 2 study
- (2016) Sung Hee Lim et al. CANCER
- Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings
- (2016) Rodrigo Barbosa de Aguiar et al. CANCER LETTERS
- Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein
- (2016) Yu Wang et al. CANCER LETTERS
- Abstract 3852: U3-1784, a human anti-FGFR4 antibody for the treatment of cancer
- (2016) Rene Bartz et al. CANCER RESEARCH
- FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
- (2016) Elie Traer et al. CANCER RESEARCH
- Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors
- (2016) Anette Sommer et al. CANCER RESEARCH
- Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma
- (2016) Priya Chudasama et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
- (2016) Noah M. Hahn et al. CLINICAL CANCER RESEARCH
- A place for precision medicine in bladder cancer: targeting the FGFRs
- (2016) Erica di Martino et al. Future Oncology
- Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma
- (2016) Chengfang Li et al. HUMAN PATHOLOGY
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
- (2016) MASARU KATOH INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- FPA144-001: A first in human study of FPA 144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody in patients with advanced solid tumors.
- (2016) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients
- (2016) Deborah T. Blumenthal et al. JOURNAL OF NEURO-ONCOLOGY
- Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression
- (2016) Eric Polley et al. JNCI-Journal of the National Cancer Institute
- New and emerging targeted treatments in advanced non-small-cell lung cancer
- (2016) Fred R Hirsch et al. LANCET
- Molecular Modeling, de novo Design and Synthesis of a Novel, Extracellular Binding Fibroblast Growth Factor Receptor 2 Inhibitor Alofanib (RPT835)
- (2016) Ilya Tsimafeyeu et al. Medicinal Chemistry
- FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival
- (2016) Soomin Ahn et al. MODERN PATHOLOGY
- Characterization of FN1–FGFR1 and novel FN1–FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors
- (2016) Jen-Chieh Lee et al. MODERN PATHOLOGY
- Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation
- (2016) K. N. Nelson et al. MOLECULAR CANCER RESEARCH
- E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
- (2016) S. Watanabe Miyano et al. MOLECULAR CANCER THERAPEUTICS
- ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma
- (2016) Takashi Futami et al. MOLECULAR CANCER THERAPEUTICS
- Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain
- (2016) Ling Jin et al. MOLECULAR THERAPY
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- (2016) Serena Nik-Zainal et al. NATURE
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
- (2016) Joshua D Campbell et al. NATURE GENETICS
- Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer
- (2016) Louise Carter et al. NATURE MEDICINE
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
- (2016) Aaron N Hata et al. NATURE MEDICINE
- Advances in the molecular genetics of gliomas — implications for classification and therapy
- (2016) Guido Reifenberger et al. Nature Reviews Clinical Oncology
- Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
- (2016) Gianantonio Rosti et al. Nature Reviews Clinical Oncology
- Limits to Personalized Cancer Medicine
- (2016) Ian F. Tannock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Dysregulated FGF signalling in neoplastic disorders
- (2016) Yasmine Tanner et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Coming-of-Age of Antibodies in Cancer Therapeutics
- (2016) B. Vijayalakshmi Ayyar et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Therapeutics Targeting FGF Signaling Network in Human Diseases
- (2016) Masaru Katoh TRENDS IN PHARMACOLOGICAL SCIENCES
- Amplification of FGFR1 gene and expression of FGFR1 protein is found in different histological types of lung carcinoma
- (2016) Vitor Sousa et al. VIRCHOWS ARCHIV
- Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer
- (2016) Masakazu Yashiro WORLD JOURNAL OF GASTROENTEROLOGY
- Molecular heterogeneity in the novel fusion gene APIP-FGFR2: Diversity of genomic breakpoints in gastric cancer with high-level amplifications at 11p13 and 10q26
- (2016) Takashi Okuda et al. Oncology Letters
- Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- (2016) Lipika Goyal et al. Cancer Discovery
- High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
- (2016) A. Pearson et al. Cancer Discovery
- Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression
- (2016) Eric Polley et al. JNCI-Journal of the National Cancer Institute
- Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
- (2016) R. F. Sweis et al. Cancer Immunology Research
- Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon
- (2016) Claire Rooney et al. PLoS One
- Myeloid and Lymphoid Neoplasm With Abnormalities of FGFR1 Presenting With Trilineage Blasts and RUNX1 Rearrangement
- (2015) Kirthi R. Kumar et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Molecular Characterization of Apocrine Salivary Duct Carcinoma
- (2015) Simion I. Chiosea et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors
- (2015) A. W. Tolcher et al. ANNALS OF ONCOLOGY
- A model of BCR-FGFR1 driven human AML in immunocompromised mice
- (2015) John K. Cowell et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeting FGFR Signaling in Cancer
- (2015) M. Touat et al. CLINICAL CANCER RESEARCH
- Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma
- (2015) K. Agelopoulos et al. CLINICAL CANCER RESEARCH
- Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas
- (2015) R. A. Toledo et al. CLINICAL CANCER RESEARCH
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations
- (2015) Leandro H. Gallo et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation
- (2015) Christof Scheid et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity
- (2015) Camillo Porta et al. Future Oncology
- FGFR2 regulates Mre11 expression and double-strand break repair via the MEK-ERK-POU1F1 pathway in breast tumorigenesis
- (2015) Y.-L. Huang et al. HUMAN MOLECULAR GENETICS
- Fibroblast growth factor receptor 1 gene amplification in gastric adenocarcinoma
- (2015) Manuel H. Schäfer et al. HUMAN PATHOLOGY
- Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
- (2015) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study
- (2015) Gottfried E Konecny et al. LANCET ONCOLOGY
- Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug–drug interaction
- (2015) Millie Das et al. LUNG CANCER
- Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells
- (2015) Y. Kwak et al. MOLECULAR CANCER THERAPEUTICS
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- The influence of subclonal resistance mutations on targeted cancer therapy
- (2015) Michael W. Schmitt et al. Nature Reviews Clinical Oncology
- Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
- (2015) Helen Gharwan et al. Nature Reviews Clinical Oncology
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET-amplified patient-derived gastric cancer xenografts
- (2015) KAI LIU et al. Oncology Letters
- First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
- (2015) M. Hagel et al. Cancer Discovery
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors
- (2015) Sara A Byron et al. NEOPLASIA
- Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
- (2014) J.- C. Soria et al. ANNALS OF ONCOLOGY
- Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer
- (2014) N Cihoric et al. BRITISH JOURNAL OF CANCER
- FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study
- (2014) X Su et al. BRITISH JOURNAL OF CANCER
- Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC
- (2014) Jeremy H. Tchaicha et al. CANCER RESEARCH
- FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
- (2014) M. W. Wynes et al. CLINICAL CANCER RESEARCH
- Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
- (2014) Matthew I. Milowsky et al. EUROPEAN JOURNAL OF CANCER
- Genomic portrait of resectable hepatocellular carcinomas: Implications ofRB1andFGF19aberrations for patient stratification
- (2014) Sung-Min Ahn et al. HEPATOLOGY
- The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
- (2014) Y. Nakanishi et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Acquired resistance to TKIs in solid tumours: learning from lung cancer
- (2014) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
- (2014) J. S. Ross et al. ONCOLOGIST
- Designing a High-Throughput Somatic Mutation Profiling Panel Specifically for Gynaecological Cancers
- (2014) Vivian M. Spaans et al. PLoS One
- Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
- (2014) Li Tan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
- (2014) M. Yu et al. SCIENCE
- Structural Insights into FGFR Kinase Isoform Selectivity: Diverse Binding Modes of AZD4547 and Ponatinib in Complex with FGFR1 and FGFR4
- (2014) Julie A. Tucker et al. STRUCTURE
- Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization
- (2014) Kiyoshi Okamoto et al. ACS Medicinal Chemistry Letters
- Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
- (2014) Y. Y. Janjigian et al. Cancer Discovery
- Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy
- (2014) M. Fernanda Amary et al. Cancer Medicine
- Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties
- (2013) Françoise Bono et al. CANCER CELL
- FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
- (2013) L. Xie et al. CLINICAL CANCER RESEARCH
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- (2013) F. Andre et al. CLINICAL CANCER RESEARCH
- Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer
- (2013) Eva Pros et al. INTERNATIONAL JOURNAL OF CANCER
- Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients
- (2013) Youngwook Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer
- (2013) Matthias Preusser et al. LUNG CANCER
- FGF Receptors: Cancer Biology and Therapeutics
- (2013) Masaru Katoh et al. MEDICINAL RESEARCH REVIEWS
- Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy
- (2013) Jeffrey S Ross et al. MODERN PATHOLOGY
- Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells
- (2013) G. E. Konecny et al. MOLECULAR CANCER THERAPEUTICS
- S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
- (2013) M. F. Burbridge et al. MOLECULAR CANCER THERAPEUTICS
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
- (2013) David T W Jones et al. NATURE GENETICS
- Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance
- (2013) Hongtai Zhang et al. NATURE GENETICS
- Gastric cancer—molecular and clinical dimensions
- (2013) Roopma Wadhwa et al. Nature Reviews Clinical Oncology
- Novel fusion transcripts in human gastric cancer revealed by transcriptome analysis
- (2013) H-P Kim et al. ONCOGENE
- Activating Somatic FGFR2 Mutations in Breast Cancer
- (2013) Nadine Reintjes et al. PLoS One
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers
- (2013) Yi-Mi Wu et al. Cancer Discovery
- Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer
- (2013) M. T. Herrera-Abreu et al. Cancer Discovery
- AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
- (2012) P. R. Gavine et al. CANCER RESEARCH
- 621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors
- (2012) P. ODonnell et al. EUROPEAN JOURNAL OF CANCER
- The transcriptional landscape and mutational profile of lung adenocarcinoma
- (2012) J.-S. Seo et al. GENOME RESEARCH
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma
- (2012) Eun-Jung Jung et al. HUMAN PATHOLOGY
- FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma
- (2012) Eleonora Brunello et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- The landscape of cancer genes and mutational processes in breast cancer
- (2012) Philip J. Stephens et al. NATURE
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- (2012) Martin Peifer et al. NATURE GENETICS
- Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
- (2012) V Chell et al. ONCOGENE
- Correction: FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
- (2012) Sara A. Byron et al. PLoS One
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
- (2012) V. Guagnano et al. Cancer Discovery
- E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- (2011) Ezia Bello et al. CANCER RESEARCH
- Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine
- (2011) Joanna D Holbrook et al. Journal of Translational Medicine
- Emerging therapeutic targets in endometrial cancer
- (2011) Konstantin J. Dedes et al. Nature Reviews Clinical Oncology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling
- (2010) A. Bai et al. CANCER RESEARCH
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
- (2010) N Turner et al. ONCOGENE
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
- (2009) F. Andre et al. CLINICAL CANCER RESEARCH
- Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development
- (2009) Edoardo Missiaglia et al. GENES CHROMOSOMES & CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started